Eli Lilly's Alzheimer’s win; Astellas joins buyers' club with $5.9B deal; $540M biotech IPO; Historic RSV vaccine OK; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
What a week! We’ve packed quite a bit in this issue, including a lot of in-depth, original reporting. If you had any of these stories open in a tab but hadn’t gotten to it yet, grab a coffee and dig in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.